简介内容:ODN 21595, a guanine-modified inhibitor targeting TLR7 and TLR9, effectively inhibits the release of IFN-α and IL-6 without exhibiting cytotoxicity. It also reduces the expression of CD86 and HLA-DR, showcasing potential for systemic lupus erythematosus (SLE) research [1].